Research

Everything You Need to Know About FFB Canada’s Patient Registry

February 6th, 2018 by FFB Canada

Fill out the online form on our Patient Registry page to learn more about how you can enroll. Click here to download a printable version of this article/fact sheet: PDF/Word. The Patient Registry is a secure medical database that was designed to connect people living with inherited retinal diseases (IRDs) to clinical trials, to improve…

Read More

Four Vision Research and Treatment Trends to Watch in 2018   

January 22nd, 2018 by FFB Canada

With the December 2017 announcement that the world’s first ocular gene therapy had received approval by the U. S. Food and Drug Administration (FDA), there’s no doubt that 2017 was a landmark year for gene therapy. Looking back, 2017 was a year of firsts, including the first stem cell therapy clinical trial for macular degeneration…

Read More

2017 in Review: The Most-Read FFB Stories of 2017

December 22nd, 2017 by FFB Canada

At the FFB, we love writing about vision research. In 2017, we wrote more than 50 stories to share news about stem cell discoveries, CRISPR gene-editing, promising new drug therapies, and emerging treatments for blinding eye disease. Have you read them all? The best place to start is with our top 10 most-read stories of…

Read More

First gene therapy for a blinding eye disease receives FDA approval

December 19th, 2017 by Dr. Mary Sunderland

Today we are celebrating the FDA’s pathbreaking approval of Luxturna. We have been following the development of Luxturna closely. Today’s landmark FDA approval makes Luxturna the first gene therapy approved in the US that targets a disease caused by mutations in a specific gene. The next steps involve determining the price for Luxturna, which poses…

Read More

Survival of the Fittest: Sustaining Cells Through Transplantation

December 18th, 2017 by Dr. Chad Andrews

In many retinal diseases, vision loss occurs when cells that are crucial for vision are damaged or lost. This is the case, for example, in age-related macular degeneration (AMD), retinitis pigmentosa, choroideremia, and Stargardt disease. To reverse vision loss resulting from these and similar diseases, we need to develop and refine our ability to replace…

Read More

Understanding the Retina: AMD and Exploratory Science

December 1st, 2017 by Dr. Chad Andrews

In medicine, innovative treatments don’t emerge out of thin air; they are the result of a series of advancements in our understanding of how genes, molecules, and cells interact. The human eye is no stranger to this rule. In fact, there is still much we don’t understand about the genetic and cellular foundations of sight….

Read More

The Value of iPSCs for Stem Cell Therapy

November 22nd, 2017 by Dr. Chad Andrews

Stem cell therapy has emerged as one of the most promising approaches in the fight to end blindness, and Dr. Gilbert Bernier’s research has played an enormous role in pushing the field forward. By developing new techniques to turn induced pluripotent stem cells (iPSCs) into sheets of cone photoreceptors, Dr. Bernier and his team are…

Read More